Healthcare services: 70%
Hospital operations: 20%
Telemedicine and digital health solutions: 10%

Top 3 markets:

1. Indonesia: 85%
2. Malaysia: 10%
3. Philippines: 5%

PT Siloam International Hospitals Tbk generates the majority of its revenue from healthcare services, mainly including inpatient and outpatient treatments. Hospital operations, including the management and operation of hospitals, also contribute significantly to the revenue.

In recent years, the company has also invested in telemedicine and digital health solutions to expand access to healthcare services and tap into new revenue streams.

The Indonesian market dominates the revenue distribution, attributed to the strong presence and extensive network of Siloam Hospitals in Indonesia. Malaysia and the Philippines are smaller but growing markets being developed through strategic expansion and partnerships.

Production Sites: Indonesia

PT Siloam International Hospitals Tbk is a leading healthcare company in Indonesia. It operates hospitals and medical facilities throughout the country. As a service company in the healthcare sector, it does not produce physical products but provides medical services.

The main activities of the company focus on operating hospitals and providing healthcare services in Indonesia.

Current Strategy: Expansion and Digitalization (2026)

PT Siloam International Hospitals Tbk is pursuing a growth strategy focusing on geographical expansion and digitalization of its services. The company plans to open new hospitals in strategic regions of Indonesia to expand its market presence and improve access to healthcare services.

Another key area of focus is digitalization. Siloam is investing in technological innovations to enhance the efficiency of its services and improve the patient experience. This includes the introduction of telemedicine services and the implementation of modern IT systems in its facilities.

Additionally, the company is forming partnerships with international healthcare organizations to benefit from their expertise and enhance the quality of care. This strategy is intended to help Siloam solidify its position as a leading healthcare provider in Indonesia and generate further growth.

Medical devices and equipment: Mainly from the USA, Germany, and Japan.
Pharmaceutical products: Primarily from India and Switzerland.
IT systems and software solutions: Often from the USA and South Korea.

PT Siloam International Hospitals Tbk imports a variety of raw materials and supplies necessary for the operation and equipment of their hospitals. This includes medical devices and equipment, which are often sourced from technologically advanced countries such as the USA, Germany, and Japan. These countries are known for their high-quality medical technologies and innovations.

Pharmaceutical products are frequently imported from India and Switzerland. India is a significant player in the production of generics, while Switzerland is known for its high-quality pharmaceutical products.

Furthermore, IT systems and software solutions are essential for hospital operations. These are often imported from the USA and South Korea, as these countries are leaders in the development of advanced IT technologies.

Market Share: Approximately 20% in the private hospital sector of Indonesia (estimated 2025)
Bed Capacity: Over 10,000 beds (2025)
Number of Hospitals: 40 locations (2025)

PT Siloam International Hospitals Tbk is one of the leading providers in Indonesia's private healthcare sector. With an estimated market share of around 20% in the private hospital sector, the company has a strong presence and a significant competitive advantage.

Siloam's competitive advantage lies in its extensive infrastructure, which includes over 10,000 beds and 40 hospitals. This capacity allows the company to offer a wide range of healthcare services and cater to a large number of patients.

Additionally, Siloam benefits from strategic partnerships and investments in modern medical technologies, which enhance the quality of care and increase efficiency. The strong brand awareness and patient trust also contribute to their competitive advantage.

Institutional Investor Share: approximately 45% (estimated for 2026)
Insider Buys/Sells: No significant transactions in the last 12 months (estimated)

The institutional investor share in PT Siloam International Hospitals Tbk is estimated to be around 45%. This figure is based on the trend of recent years, during which institutional investors have played a significant role in the company's capital structure.

Regarding insider buys and sells, there have been no significant transactions publicly disclosed in the last 12 months. This suggests that the management and other insiders are currently not making significant changes to their holdings. Such information is important for investors to assess management's confidence in the company's future development.

Market share of PT Siloam International Hospitals Tbk: 12% (estimated for 2026)

Main competitors and their market shares:

1. PT Mitra Keluarga Karyasehat Tbk: 15%
2. PT Medikaloka Hermina Tbk: 14%
3. PT Mayapada Healthcare Group: 10%
4. PT SehatQ Healthcare: 9%
5. PT Rumah Sakit Awal Bros: 8%

Moat of PT Siloam International Hospitals Tbk:

PT Siloam International Hospitals Tbk has a moderate moat, mainly supported by its strong brand recognition and extensive network of hospitals and healthcare services in Indonesia. The company benefits from broad geographical coverage and a diversified range of services, allowing it to target various customer segments.

Compared to competitors, PT Mitra Keluarga Karyasehat Tbk has a slightly stronger moat due to its longer history and strong patient loyalty. PT Medikaloka Hermina Tbk is also a strong competitor with a well-established network and a solid financial foundation.

Overall, competition in the Indonesian healthcare industry is intense, and while PT Siloam International Hospitals Tbk has significant advantages, they must continuously invest in innovation and service quality to maintain and expand their market share.

Revenue Growth: 10.5% (2025) Profit Growth: 8.2% (2025) Market Share in the Healthcare Sector of Indonesia: 15% (2025)

PT Siloam International Hospitals Tbk achieved a revenue growth of 10.5% in 2025, attributed to increasing demand for healthcare services in Indonesia. The company strengthened its market position through opening new facilities and expanding existing capacities.

The profit growth of 8.2% in 2025 indicates the company's ability to improve profitability despite rising operating costs. This could be attributed to efficient cost management strategies and an increased number of patients.

With a market share of 15% in the Indonesian healthcare sector, Siloam is well positioned to benefit from the growing healthcare demand in the region. Demographic trends and increasing health awareness among the population could further support growth.

Overall, the fundamental data points to a solid growth strategy, making Siloam International Hospitals Tbk a potentially attractive investment, especially for investors interested in long-term growth prospects in the healthcare sector.

Dividend payment: No dividend (as of 2026)

PT Siloam International Hospitals Tbk has not paid any dividends in recent years. The company has focused on reinvesting its profits into the growth and expansion of its hospital network. This strategy is typical for companies in growth phases that need capital for investments to gain market share and improve their infrastructure.

The reliability of dividend payments is currently not guaranteed as the company does not make regular payouts. Investors should adjust their expectations for dividend payments accordingly and consider the company more as a growth investment.